Denali Therapeutics Inc.
Anti-TREM2 antibodies and methods of use thereof

Last updated:

Abstract:

In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.

Status:
Grant
Type:

Utility

Filling date:

15 Jan 2021

Issue date:

21 Sep 2021